CLDI — Calidi Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $11.30m
- $18.04m
Annual cashflow statement for Calidi Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -7.94 | -10.9 | -25.4 | -29.2 |
| Depreciation | ||||
| Non-Cash Items | 1 | 1.4 | 8.38 | 8.08 |
| Unusual Items | ||||
| Purchased R&D | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 2 | 1.61 | 3.57 | -6.24 |
| Change in Prepaid Expenses | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | -4.83 | -7.77 | -13.2 | -27 |
| Capital Expenditures | -0.351 | -0.206 | -0.428 | -0.585 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | -0.037 | -0.009 | -0.066 | 0.107 |
| Change in Net Investments | ||||
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | -0.388 | -0.215 | -0.494 | -0.478 |
| Financing Cash Flow Items | 0 | 6.78 | 8.04 | 3.37 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 4.7 | 9.81 | 12.1 | 29 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | -0.514 | 1.82 | -1.65 | 1.58 |